Int. J. Curr. Res. Med. Sci. (2025). 11(2): 63-77

International Journal of Current Research in Medical Sciences

ISSN: 2454-5716

(A Peer Reviewed, Indexed and Open Access Journal)

www.ijcrims.com

Review Article

Volume 11, Issue 2 -2025

DOI: http://dx.doi.org/10.22192/ijcrms.2025.11.02.008

Artificial intelligence and machine learning in therapeutic drug monitoring: Revolutionizing dosing and clinical decision support

Ravva. Nikhil Gupta[1], Chilukoti. Mahesh Babu[2]

[1] Pharm.D, Scientific Medical Writer. *nikhilguptaravva@gmail.com*

[2] Pharm.D,Clinical Pharmacist.*Maheshchilukoti07@gmail.com*

Corresponding author: Ravva. Nikhil Gupta

nikhilguptaravva@gmail.com

Abstract

Therapeutic drug monitoring (TDM) is such an area that focuses on ensuring the right doses are given to reach the maximum therapeutical efficacy and the lowest possible adverse effects in precision medicine. Until now, TDM was primarily based on classical pharmacokinetic (PK) and pharmacodynamic (PD) models, requiring extensive laboratory monitoring and manual adjustments for behavioral assessment, eventually perfected by artificial intelligence (AI) and machine learning (ML). The demand for real-time, data-derived doses and clinical decision support is fulfilled by TDM enabled by AI and ML technologies. Models based on AI use the enormous databases of patients such as drug metabolism combined with genetic and real-time physiological factors for fine dosing. The machine learning algorithms such as neural networks, Bayesian models, and decision trees have shown significant application in levels of optimising biomolecules over time across multiple therapeutic areas including antimicrobial therapy, antiepileptic drugs, immunosuppressants, and oncology treatments. In addition, the AI-based Clinical decision support systems also help personalize dosage through EHR integration into the system and hence improve treatment outcomes and reduce drug toxicity. However, these advances in technology do face various challenges such as poor quality of data, non-interpretability of models, regulatory challenges, and several ethical dilemmas on the generalization of these technologies in the clinical environment. This article reviews the contributions made by AI and ML in TDM, their applications, benefits, limitations, and future scope in furthering precision medicine.

Keywords: Therapeutic Drug Monitoring (TDM), Artificial Intelligence (AI), Machine Learning (ML), Clinical Decision Support System (CDSS), Precision Medicine, Pharmacokinetics, Pharmacodynamics, Personalized Dosing, Drug Monitoring, AI in Healthcare

Introduction

TDM is a currently very important clinical practice of measuring the drug concentrations in a blood sample in a patient to the effective prescribing for therapeutic benefit with minimized toxicity. It is very important for drugs that have a low therapeutic index, where a minor change in drug concentration may result in failure of the treatment and sometimes lead to severe adverse effects. TDM includes the managing of medications such as antibiotics (vancomycin, aminoglycosides)- antidepressants (amitriptyline)- some anticoagulants (warfarin)- immunosuppressants (tacrolimus, cyclosporine)- antiepileptics (such as phenytoin and valproate), in which an accurate dose is very important. Then taking into account individualized specific elements relating to the patient, such as age, weight, renal and hepatic function, genetics, and possible drug interactions, TDM has a defining role in the field of precision medicine, directing treatment strategies toward treating patients rather than following generic dosing regimens. It allows drug action to be optimized in a personalized way, reducing side effects and improving patient outcome, and thus TDM becomes a key tool in modern clinical pharmacology and personalized health care.[1,2,3]

Key principles of Therapeutic drug monitoring (TDM)

1. Individualized Dosing

A response to any medication is unique with respect to each patient, owing to variations in age, mass, organ function, genetic differences, and coexistence of diseases. Therefore, TDM individualizes dosing on grounds of these variables in order to achieve maximum therapeutic effect with minimum toxicity.

2. Therapeutic Range Targeting

The TDM consists of keeping the concentrations of drugs within a defined therapeutic window, that is able to dose, inhibit the action of toxic effects. Drugs having a narrow therapeutic index (NTI) should be closely monitored to avoid underdosing (ineffectiveness) or overdosing (toxicity). Examples include warfarin, lithium, and digoxin.

3. Timing of Sample Collection

Proper timing of blood sample draw in TDM is crucial to achieving accurate results. Peak levels and trough levels must be measured at appropriate intervals so that dose adjustments can be made. Any discrepancy in sampling time will mislead and might lead to an unwanted dose change.

4. Integration of Pharmacokinetics and Pharmacodynamics

A drug's absorption, distribution, metabolism, and excretion (ADME) have significant roles in dose optimization. In addition, pharmacodynamic effects such as drug receptor interactions and variability in responses present a further dimension to therapeutic outcome. Thus, TDM combines these aspects in providing individualized treatments.

5. Clinical Interpretation and Decision-Making

The TDM requires the interpretation together with the patient clinical condition, laboratory findings, and other drug interactions. therefore, physicians and pharmacists analyze drug levels and disease condition changes to treatment effects in adjustment of therapy while improving the patient safe and efficacy.[4,5,6]

Current methods used for Therapeutic drug monitoring (TDM)

1. Immunoassays

Immunoassays are increasingly used in so-called toxicological testing and therapeutic drug monitoring in clinical laboratories because of rapid turnaround times and the ease of automation. The method normally depends on antigen-antibody reactions for the detection and quantitation of drugs in biological fluids.

Examples of such immunoassays include ELISA, RIA, and FPIA. Although immunoassays are very sensitive, often a lack of specificity because of cross-reactivity with structurally similar compounds can lead to false-positive or false-negative results.

2. High-Performance Liquid Chromatography (HPLC)

HPLC chromatography is often used for Therapeutic Drug Monitoring, offering excellent specificity and precision. It, therefore, separates drug molecules based primarily on specific chemistries with accurate quantification. HPLC is suitable for monitoring the complex metabolism of drugs such as anticonvulsants and immunosuppressants. However, HPLC is expensive, laborious, and slow when compared with immunoassays.

3. Liquid Chromatography-Mass Spectrometry (LC-MS/MS)

The gold standard method for TDM is LC-MS/MS, which is a method with outstanding sensitivity and specificity and the ability to analyze multiple drugs at the same time. It couples liquid chromatography (LC) with mass spectrometry (MS) to identify and quantify drugs by minimal cross-reactivity. LC-MS/MS is used to monitor drugs across the spectrum of antibiotics, anticancer therapies, immunotherapy, and psychoactive medications, but costs and technical complexity limit its routine laboratory use in the smaller lab environment.[7,8,9]

4. Gas Chromatography-Mass Spectrometry (GC-MS)

GC-MS is another highly specific and sensitive technique used in TDM, particularly for volatile GC-MS is one of the other remarkably specific and sensitive techniques employed in TDM with regard to volatile compounds such as antiepileptic and anesthetic drugs. Molecular investigation offers a greater advantage in forensic toxicology and drug abuser monitoring. However, it requires a lengthy sample preparation process, which limits its applicability in routine clinical TDM use.

5. Capillary Electrophoresis (CE)

Capillary electrophoresis is a promising, emerging, and latest technique in TDM that has the ability to effectively separate drug molecules according to the charge and size by using an electric field. It is also a method that requires only very little amounts of sample volumes, has very high efficiency, and also very much high resolution. One of the major setbacks of this technique is that it has not yet been widely applied in routine clinical practice because the instruments, as well as training, are provided but not readily available to health care providers.

6. Spectrophotometric Methods

Ultraviolet-visible (UV-Vis) and infrared (IR) spectrophotometry are sometimes used in TDM for simple drug concentration measurements. These methods are cost-effective and easy to use but lack the sensitivity and specificity required for precise drug monitoring, making them less suitable for drugs with narrow therapeutic windows.[10,11]

Challenges in traditional TDM approaches

1. Interpatient and Intrapatient Variability

Genetic, organ functional, co-morbidity, as well as lifestyle variability contribute to the difficulty of having similar levels of therapeutic efficacy. Sometimes patients, though with the same conditions, often require different doses, while changes in the metabolism of an individual with time can add further complexity to the changing dose, thus increasing the chance of underdosing and an overdose and, therefore, increased frequency of monitoring and individualized treatment.

2. Nonlinear and Unpredictable Pharmacokinetics

Phenytoin is yet another drug exhibiting nonlinear pharmacokinetics, which means that small dose changes may result in disproportionation in

concentration changes. Predictable pharmacokinetics become even more complicated when altered protein binding, drug-drug interactions, enzyme induction, and enzyme inhibition interplay with the changes in concentration. The long half-life of digoxin adds to the still greater complication of delay in achieving steady-state, making highly exigent requirements for sampling times and expertise in order to avoid toxicity and subtherapeutic concentrations.

3. Dependence on Clinician Expertise

Interpreting TDM results requires specialized pharmacokinetic knowledge. Timing, metabolism considerations, or adjustments in doses can lead to the non-fulfillment of treatment. One possible constraint faced by some settings is limited availability of trained personnel for effective monitoring. Misinterpretation of results could result in toxicity or therapeutic failure; therefore, there is a need for automated decision-support tools to work on decreasing the burden of clinicians and improving accuracy.

4. Sample Collection and Timing Errors

According to proper TDM principles, blood samples must be accurately collected during the trough or peak level, as required for the particular drug. Any improper timing and handling of blood samples can lead to erroneous dose adjustments, thus harming the patient. Inconsistent collection practices across different healthcare environments are variables that render the results invalid. Training should be emphasized for the staff in order to standardize practices and alleviate sampling and processing errors.

5. Laboratory and Turnaround Time Limitations

Classic therapeutic drug monitoring (TDM) methods involve pharmacokinetic laboratory assessments, which usually do not provide results in time for timely dose adjustments. In the intensive care unit, a study that takes long to report results could mean the difference between prolonged toxicity or therapeutic failure. Differences in laboratory techniques and reporting from institution to institution lower the reliability of results and hinder comparisons between institutions and clinical decisions.

6. Cost and Resource Constraints

The lab equipment, trained personnel, and standardized set of tests required for TDM render it resource intensive. In settings where resources are low, TDM cannot be effectively applied for timely and accurate guidance on dose adjustments, necessitating the continual assumption of doses, which increases the chances of suboptimal therapy. Cost may be another factor forbidding the use of TDM on a wider scale; frequent monitoring and specialized tests may not be affordable.[12,13,14]

The role of artificial intelligence (AI) and machine learning (ML) in optimizing TDM

Artificial intelligence (AI) and machine learning (ML) thereby change therapeutic drug monitoring (TDM) from being static tools to being dynamic predictive and adaptive solutions for the optimization of drug dosing. Currently, AI models analyze longitudinal patient databases, capturing all demographics, genetics, comorbidities, laboratory values, real-time drug concentration levels, and so forth, to predict advantages to the specific patient dose in an evidence-based model. For example, machine learning algorithms-such as neural networks, support vector machines, and Bayesian forecasting models-find use in improving pharmacokinetic-pharmacodynamic modeling which could potentially enable on-demand adjustment of dosage from a minimum of blood sampling requirements. Their clinical applications are also within CDSSs, which integrate TDM data into electronic health records and recommend customized doses to providers. With the help of AI, precision medicine also incorporates identification of patient subgroups to whom innate biological variations or different disease states would ideally require different dosing strategies. Thus, while automating these complicated calculations, they reduce clinician

workload and enhance accuracy in dosing, making a more efficient and personalized approach available in TDM, ultimately improving patient outcomes while decreasing adverse drug reactions.[15,16]

AI and ML techniques used in Therapeutic drug monitoring (TDM)

AI and ML indeed brought a major alteration in Therapeutic Drug Monitoring (TDM), creating the possibility for accurate, data-based, and adaptive doses of drugs. Historically, TDM has been entirely based on population pharmacokinetics (PK) and pharmacodynamics (PD) that rarely consider individual variations. New AI/ML techniques combined some vast specific data-patient details, such as genetic, metabolic, and physiological parameters, to recommend personalized drug doses, thus increasing the efficacy and decreasing toxicity, and maximizing better clinical decision-making.

Supervised Learning (Regression & Classification Models)

Supervised learning algorithms can be useful for TDM in predicting drug concentration levels, determining the risk factors for adverse drug reactions (ADRs), and optimizing dosing regimens. Linear and logistic regression models helped define relationships between drug dose and serum concentration, as well as other patient-specific features, such as renal and hepatic function. Random forests and decision trees are examples of patient features the age, weight, coexistences, and genetic markers to classify the patients into different risk categories and offer them personalized dosing approaches. Through the collection of patient data, these models will tend to improve gradually and allow for real-time optimization of treatment regimens.[17,18]

Unsupervised Learning (Clustering & Pattern Recognition)

The techniques in unsupervised learning are especially apt for discovering hidden patterns in massive pharmacokinetic databases. In this way, K-means clustering and principal component analysis (PCA) could group patients based on the metabolistic behavior of a drug in order to identify subpopulations that respond differently to that drug. For example, clustering algorithms are used in immunosuppressive drug therapy to categorize transplant patients based on the absorption and clearance rates of drugs for individual adjustments of drug dosage. Automatic recognition of drug response patterns for patients can enhance the precision of TDM, thus helping to avoid subtherapeutic or toxic drug levels.

Deep Learning (Neural Networks & Reinforcement Learning)

Deep-learning models mainly, the artificial neural networks, study the complex interactions between drug metabolism, genetic variations, and physiological parameters. These models have been effectively used for predicting drug-drug interactions and drug dosing in cancer chemotherapy according to tumor characteristics. Dosing strategies in adaptive dosing are significantly useful under reinforcement learning (RL) since they continually learn dosing strategies based on real-time patient feedback. The RL has shown promise in adapting insulin doses dynamically in diabetes management and anticoagulant therapy, leading to optimal therapeutic effectiveness and minimal associated risk.[19,20]

Natural Language Processing (NLP) for Clinical Data Analysis

From unstructured medical data such as electronic health records (EHRs), clinical notes, and pharmacovigilance reports, Natural Language Processing (NLP) can extract useful insights. AI-based NLP algorithms explore patient histories and laboratory reports, and real-world evidence to alert the users to suspicious adverse drug reactions (ADRs) and drug-drug interactions (DDIs). Thus, for example, a signal of nephrotoxicity in patients receiving vancomycin or hepatotoxicity in patients undergoing chemotherapy can be automatically derived, allowing timely intervention and higher medication safety.

As a whole, these AI and ML techniques have been extremely useful to the art of TDM sophistication and will aid clinical decisions in improving patient safety and reducing the risks for optimizing drug efficacy. Here TDM will advance from standard dosing recommendations for drugs to individualized regimens, a significant step forward in precision medicine.[21,22]

AI/ML integration in Therapeutic drug monitoring (TDM)

Therapeutic drug monitoring or TDM defines precision medicine by measuring the concentration of drugs in the body of a patient for optimizing an appropriate drug dose for maximizing efficacy with minimal toxicity. TDM is mostly pharmacokinetic dependent and, at times, pharmacodynamic-related, when combined with the clinical expertise of the prescriber, who might use these models to develop effective alterations in dosing levels. However, such dose optimization is often complicated due to inter-individual variability owing to genetic, physiological, and environmental factors. The emergent applications of Artificial Intelligence (AI) and Machine Learning (ML) have a transforming capacity in TDM by imparting enhanced predictive capacity, automating processes, and individualized treatment recommendations. These applications of AI/ML in TDM will thus be the future for more accurate doses, better safety for patients, and fewer adverse drug reactions.).

1. AI-Driven Dose Optimization and Personalization

The optimization of AI-assisted doses is converting the new paradigm into therapeutic drug monitoring (TDM), where the custom dosing of drugs for patients is evaluated according to the methods of machine learning (ML) and predictive analytics. Current dosing practices use a fixed guideline for dosage that often tends to overlook the inter-individual variability caused by genetics, metabolism, organ function, and comorbidities. In contrast, AI optimization begins by considering and analyzing vast amounts of patient background data, including demographic information, laboratory results, and pharmacogenomic markers, towards real-time dynamic adjustment of dosing for an individual patient. ML algorithms such as deep neural networks and reinforcement learning keep updating their predictions by learning from constantly incoming streams of clinical data, thus ensuring the maintenance of optimum drug levels with the least risk of toxicity. This AI-influenced dosing paradigm is an indispensable part of the therapeutic management of narrow therapeutic index drugs such as anticoagulants, immunosuppressants, and chemotherapeutics, for which even the slightest dose shifts can cause life-threatening adverse effects. AI-powered real-time monitoring systems also implement wearable biosensors, which can follow drug metabolism and automatically adjust dosing, thereby embodying a precision medicine principle that promotes safety and therapeutic effectiveness.[23,24]

2. AI-Based Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling

It is also important that AI modeling and prediction include features differentiating among populations and geographical sites, as well as prediction in relation to time, particularly in safety and efficacy trials. Population-based drug response has always been the strain-and-brain-typical fallacy of new open-ended static equations used in PK/PD studies.Machine learning and deep learning add clinical interpretation to model prediction using extensive clinical datasets. From the population-wide database including genetics-an unbiased acquisition-and speed of metabolism to disease-related parameters, these models now predict.

Drug concentration-time profiles can be precisely predicted through the usage of machine learning algorithms that process enormous patient data, rather than relying on traditional compartmental models. These superb tools of AI can simulate multifaceted drug interactions, discover nonlinear relationships in parameters of PK/PD, and modify the dose regimens continuously. For example, AI-based pharmaceutical kinetics modeling in antibiotics such as vancomycin helps adjust the dose regimens, thereby lessening the effects of

nephrotoxicity while still achieving the efficacy in critically ill patients. Furthermore, PD modeling powered by AI predicts individual patient drug responses, which can improve precision dosing strategies in oncology, neurology, and cardiology.

It incorporates AI-induced benefit into the PK/PD modeling personalized medicine: trial-and-error dose approaches are thus reduced. AI models can learn and improve continuously with the help of fresh patient data: thereby refining prediction and enhancing therapeutic results. Yes, it advances clinical decision-making, reduces adverse effects, and improves the effectiveness of drug use. All this will take pharmacotherapy an additional step towards the future of patient-centricity.[25,26]

3. Predictive Analytics for Adverse Drug Reactions (ADRs)

Among the many concerns in Therapeutic Drug Monitoring is the occurrence of adverse drug reactions (ADRs), which add to morbidity and mortality in vulnerable populations. Advancements in AI put predictive analytics at the forefront in helping identify patients at elevated risk of drug-related toxicities by mining historical information of TDM, clinical parameters, and genetic predispositions. Therefore, decision tree algorithms and deep neural networks assess a patient's medication history, laboratory results, and comorbid conditions to predict the likelihood of ADR occurrence. For example, AI models have been built to predict the nephrotoxic potential of aminoglycosides or vancomycin, hence allowing a proactive adjustment of doses by clinicians. In addition, ML-based pharmacovigilance systems continuously screen EHRs and real-world evidence for emerging safety signals, guaranteeing improved response to adverse drug events.[27,28]

4. Automated Data Interpretation and Pattern Recognition

These days, artificial intelligence-enabled automated data interpretation and pattern recognition are revolutionizing clinical decision-making by rendering insight from complex and voluminous datasets. Traditional methods of data analysis mostly depend on manual processing, posing both long turnarounds and plenty of opportunity for human error. Deep learning and natural language processing (NLP)-based AI algorithms accurately and efficiently process structured or unstructured medical data such as laboratory reports, imaging interpretations, electronic health records (EHRs), and genomic data to find hidden patterns and correlations.

The drug-monitoring AI models are optimizing drug dosages and predicting outcomes based on serum concentration, metabolism, and pharmacogenomic markers. Anomalies and clustering via machine learning help to assess variability in drug responses across patient populations. AI systems, for example, can detect very slight aberrations in biomarkers indicating drug toxicity or ineffectiveness, allowing for timely remedial action. AI automated data interpretation aligns with precision medicine to upgrade diagnosis and aid clinical decision-making based on evidence.[29,30]

5. Integration with Digital Health Technologies for Real-Time Monitoring

The recent trends in digital health technologies, especially those that fall under the category of wearable biosensors and mobile health applications, are paving the way for novel applications of AI in therapeutic drug monitoring (TDM). Such portable devices have AI-enabled features that track drug levels and physiological parameters (heartbeat, blood pressure and glucose levels) continuously and in real-time. By employing a series of machine learning algorithms, the processing of the data can now summon early signs of toxicity or subtherapeutic drug levels for intervention within a very short time. AI-enabled continuous glucose monitors (CGMs) optimize insulin management for diabetic patients by forecasting glycemia fluctuations and adjusting insulin doses accordingly. AI processing platforms for remote monitoring also allow clinicians to track transplant patients on immunosuppressants and ensure adherence and prevent organ rejection. For example, cloud-based AI models further improve

real-time TDM through data integration from multiple sources into a single patient's cloud-based profile, real-time patient consultations, and precision medicine applications.[31,32]

6. Drug-Drug Interaction (DDI) Detection

Artificial intelligence is detecting interactions between drugs, which is transforming medication security by identifying probable interferences that cause adverse effects or just diminished therapeutic efficacy. Recently, the types of DDI detection methods have been focused entirely on clinical guidelines and manually curated databases; hence, they often omit the potential for new interactions or individual patient factors. Such AI models analyze enormous data sets, such as EHRs, pharmacovigilance reports, and biomedical literature, to discover known and novel drug interactions with much more accuracy and efficiency.

Machine learning algorithms and NLP combine diverse sources, resulting in real-time DDI detection. Deep learning models like neural networks can identify complicated relations between drug mechanisms, metabolic pathways, and genetic predispositions for the prediction of interactions beyond standard rule-based models. Furthermore, AI-based DDI detection proves of much assistance when used in polypharmacy or situations in which many medications have been given, increasing the potential of harmful interactions with each additional drug. Incorporating AI-enabled DDI screening within clinical decision support systems will help the prescribers optimize medication regimens while decreasing adverse effects and improving patient safety.[33,34]

Clinical decision support systems (CDSS) in therapeutic drug monitoring (TDM)

As of now, AI-integrated clinical decision support systems are revolutionizing therapeutic drug monitoring through real-time evidence-based recommendations that can optimize drug therapy. Whereas traditional therapeutic drug monitoring relies entirely on manual interpretation of drug levels, pharmacokinetic models, and clinical judgment, this may lead to interindividual variability in dosing accuracy. AI pertinently contributes to this decision-making process by utilizing data points pertaining to a patient such as drug concentrations, renal and hepatic function, pre-existing genetic factors, and incidental comorbidities so that it can customize drug dosing in a way that lessens the risk of toxicity or therapeutic failure.

Machine learning (ML) and predictive analytics provide CDSS the means to continuously adjust the dosing algorithms based on real-world patient responses, improving the accuracy of the systems over time. The systems can warn the clinician regarding potential DDIs, ADRs, and general deviations from therapeutic ranges, thereby improving medication safety. AI CDSS also support adaptive dosing in critical care environments, for example, antibiotics in sepsis management or anticoagulation agents used in cardiac patients. CDSS also aids in integrating clinical workflows, assuring precision medicine, improving patient outcomes, and simplifying medication management for the healthcare provider.[35,36]

Applications

Therapeutic Area	Drugs Involved	AI/ML Applications in TDM
Infectious Diseases	Vancomycin, Aminoglycosides (Gentamicin, Amikacin), Voriconazole	AI predicts drug clearance based on renal function and inflammatory markers and optimizes dosing to prevent nephrotoxicity and resistance. Bayesian models refine the dose adjustments in real time.
Cardiovascular Diseases	Warfarin, Rivaroxaban, Amiodarone	AI-enabled pharmacogenomic models use genetic markers (CYP2C9, VKORC1, etc) to optimize anticoagulant dosing with minimum risk of bleeding.
Oncology	Methotrexate, Cisplatin, 5-Fluorouracil, Tyrosine Kinase Inhibitors (TKIs)	AI predictive models optimize chemotherapy dosing to avoid toxicity with clinical efficacy. Deep learning analyzes data from the real world for dynamic dose adjustments.
Neurology & Psychiatry	Valproate, Phenytoin, Carbamazepine, Lithium, Clozapine	AI incorporates EEG pattern and genetic polymorphisms with clinical data to dose antiepileptic drugs.
Transplant Medicine	Tacrolimus, Cyclosporine, Mycophenolate Mofetil	AI uses Bayesian forecasting and reinforcement learning to tailor immunosuppressive dose adjustment to patient-specific factors for better long-term graft survival.
Endocrinology	Insulin, Levothyroxine	Continuous glucose monitoring data provide the basis for AI modeling of optimal insulin dose adjustment, while ML optimizes the replacement of thyroid hormone through analysis of metabolic parameters and comorbidities.

Benefits and advantages of AI-driven therapeutic drug monitoring (TDM)

1. Enhanced Accuracy and Efficiency in Drug Dosing

AI TDM will ensure perfect dosing by considering data like genetics, renal function, and really current drug levels. Machine learning models will improve the optimization of drug doses and reduce the under-dosing risk or deterioration for narrow therapeutic index drugs such as vancomycin and warfarin.

2. Real-Time Monitoring and Predictive Analytics

AI facilitates continuous monitoring of drug concentrations, thus allowing real-time adjustment in doses. Predictive algorithms will also forecast the variations in drug metabolism and drug interactions and prevent adverse drug reactions (ADRs) and treatment failures.

3. Improved Patient Safety and Reduced ADRs

By integrating AI in TDM can help health care providers in developing proactive measures toward ADRs, drug-drug interactions (DDIs), contraindications, thereby increasing patient safety and reducing hospital stays caused by medication-related adverse reactions.

4. Automation and Reduced Clinician Workload

TDM using AI would perform an intricate and complex calculation and interpretation much less likely to fall into the human errors, thereby giving healthcare professionals the opportunity to spend

more time delivering and less time on mechanical data analysis.[37,38,39]

5. Personalized Medicine and Dose Individualization

AI models analyze the different genetic and metabolic variations among patients to provide personalized dosing regimens that optimize therapeutic efficacy and reduce the occurrence of adverse effects.

6. Cost-Effectiveness and Resource Optimization

TDM reduces the superior health care savings costs that directly applied by having the adverse effects avoided, optimizing drug use, and reducing stays in hospitals for patients, especially in intensive care and oncology settings

7. Enhanced Decision Support with AI-Powered Clinical Decision Support Systems (CDSS)

AI integrates TDM data into EHRs, converting what clinicians do into actionable and evidence-based decision making, thereby improving treatment precision and adherence to guideline recommendations.

8. Better Integration with Digital Health Technologies

The TDM system does integrate with many wearables, mobile health apps, and some IoT-based biosensors, enabling the monitoring of the patient remotely and improving adherence to medication out of clinics.

9. Rapid Adaptation to Changing Patient Conditions

In contrast to the traditional TDM, AI algorithms keep on changing their recommendations for drug dosing in response to the altering physiological and pathological situations adapting to the changing smooth and dynamic nature of treatment

10. Facilitating Research and Drug Development

Through AI approaches, TDM speeds up the process of drug discovery and development by detecting any patterns in the clinically relevant pharmacokinetics (PK) and pharmacodynamics (PD) data so that pharmaceutical companies create their safer and more effective therapies.[40,41]

Challenges and limitations in AI-Based therapeutic drug monitoring (TDM)

1. Data Availability and Quality Issues

In AI-based TDM, enormous datasets are needed for the training and validation processes. Real clinical data, however, may contain missing, inconsistent, and biased data which can lead to inaccurate target predictions and unreliable dosing recommendations. Also, the differences in data collection methods across hospitals and regions may hinder the generalizability of the AI models.

2. Model Interpretability and Clinical Trust

Many AI models operate as "black boxes" that are almost impossible for clinicians to understand in making a given dose recommendation. When aided by such decisions, the entire transparency of the decision-making process will raise doubts from health providers while hampering acceptance in real-life clinical practice.

3. Ethical and Legal Concerns

Artificial intelligence-based TDM handles critical patient data which give rise to issues related to data privacy, security, and compliance with standards and regulations such as HIPAA and GDPR. Liability issues arise when an AI-dosing recommendation is detrimental to a patient, and there is no clarity on whose responsibility that may lie: the clinician; AI development or the institution.

4. Integration with Existing Healthcare Systems

Legacy electronic health record (EHR) systems are present in many hospitals and clinics; most of these systems will not be able to take integration with an AI-based TDM platform. These create technical and financial barriers to complete implementation and require complete infrastructural upgrades.

5. Limited Generalizability Across Patient Populations

AI models trained on specific populations do not generalize well to patient populations with different kinds of genetics, comorbidities, or medication regimens. Personalized medicine requires highly flexible AI systems, but existing models can hardly incorporate patient variation.

6. Need for Continuous Model Updating and Validation

New drugs and treatment protocols come with new patient reactions and therefore necessitate continuous updating and re validating of the AI model. An out-of-date model, by lack of regular updates, will still give inaccurate or unsafe dosing recommendations. However, maintaining the AI model requires constant data collection, regulatory approval, and huge computational resources.[42,43]

7. Risk of Over-Reliance on AI

Though AI makes it easy for a clinician the decisions, the clinician must still follow through on dose adjustment. The outcome in a complex patient whose condition changes quickly, or in whom the AI prediction is at odds with clinical observations, will result in perverse error.

8. High Implementation Costs and Resource Requirements

To develop and deploy TDM systems based on AI technologies requires massive amounts of initial investments in data infrastructure, software development, and staff training. Many health care institutions, especially in low- and medium-resourced settings, may struggle to afford sustaining AI system integration.

9. Regulatory and Standardization Challenges

There are no existing universal regulatory frameworks for AI TDM thus rendering differences in the validation, approval, and clinical adoption processes. Maintaining compliance with the requirements of regulatory agencies, like the FDA and EMA, is still a complex challenge

10. Ethical Considerations in AI Decision-Making

Unlike dosing recommendations based on clinical guideline policies in which human practitioners exercise medical judgment to make decisions in evaluating the patient, a prescribing decision based upon AI should not have biases leading to differential therapeutic outcomes through various patient populations.

Future directions and innovations in AI-Driven TDM

Deep learning, biosensing in real time, and personalized medicine will play an advanced role in dictating the future of AI-driven Therapeutic Drug Monitoring. A considerable innovation within the arena refers to AI-driven adaptive dosing algorithms that improve drug therapy precision by being constantly updated on the basis of real-time patient data. The integration of wearable biosensors and IoT devices will allow continuous monitoring of drug levels and provide feedback to the AI models for real-time adjustments of dosing. Integration of multi-omics data—consisting of genomics, metabolomics, and proteomics—will refine AI drug pharmacokinetic (PK) and pharmacodynamic (PD) modeling for personalized medicine by fine-tuning the drug regimen based on the individual's genetics and metabolism.The utmost innovation in future AI-enabled Therapeutic Drug Monitoring (TDM) will continue to be driven by improvements in deep learning, biosensing in real-time, and personalized medicine. One such breakthrough is AI-based

adaptive dosing algorithms that are linked to real-time patient data and continuously update to increase precision in drug therapy. The coupling of biosensors and devices with the Internet of Things (IoT) will facilitate constant drug-level monitoring for an immediate response to the AI model for dynamic dose adjustment. In addition, multi-omics data sets-including genomics, metabolomics, and proteomics-will improve pharmacokinetic (PK) and pharmacodynamic (PD) modeling based on AI, resulting in true personalized medicine, whereby drug regimens are focused on an individual's genetic and metabolic profile.[44,45]

Conclusion

The revolution of Therapeutic Drug Monitoring (TDM) into data-driven potentialized dosing strategies has ensured improvements in drug efficacy without toxicity and is entirely governed by the interference of these technological advances such as AI and ML. Neural networks and Bayesian models are examples of machine learning models that fine-tune drug levels across diverse therapeutic fields, including antimicrobial therapy, immunosuppressive agents, and oncology. They instead possess the therapeutic advantages of their integration in AI-based Clinical Decision Support Systems (CDSS) with pharmacokinetic (PK) and pharmacodynamic pathways associated with patient clinical data in real time and dose efficacy dimension.

Even with all of those advances, obstacles still prevail: poor data quality, interpretation of model results, constraints in regulations, and ethical questions. Research efforts on tackling these issues through collaboration and solid clinical validation are paramount, especially in the area of AI-driven TDM implementation. AI will become another innovation factor of great importance when combined with pharmacogenomics and real-world evidence for precision medicine in optimizing therapeutic outcomes and ensuring patient safety. Successful integration of AI with routine practice in the clinic can shape the future of personalized drug therapy.

References

1. Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009 Mar;24(1):1-10
2. Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol. 1998 Aug;46(2):95-9.
3. Cremers S, Guha N, Shine B. Therapeutic drug monitoring in the era of precision medicine: opportunities! Br J Clin Pharmacol. 2016 Oct;82(4):900-2.
4. Tyson RJ, Park CC, Powell JR, Patterson JH, Weiner D, Watkins PB, Gonzalez D. Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables. Front Pharmacol. 2020 Apr 22;11:420.
5. Shipkova M, Christians U. Improving Therapeutic Decisions: Pharmacodynamic Monitoring as an Integral Part of Therapeutic Drug Monitoring. Ther Drug Monit. 2019 Apr;41(2):111-114.
6. Maranchick NF, Peloquin CA. Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis. J Clin Tuberc Other Mycobact Dis. 2024 Apr 24;36:100444.
7. Nikolin B, Imamović B, Medanhodzić-Vuk S, Sober M. High perfomance liquid chromatography in pharmaceutical analyses. Bosn J Basic Med Sci. 2004 May;4(2):5-9.
8. van Aalen EA, de Vries IR, Hanckmann ETL, Stevens JRF, Romagnoli TR, Derijks LJJ, Broeren MAC, Merkx M. Point-of-care therapeutic drug monitoring of tumour necrosis factor-α inhibitors using a single step immunoassay. Sens Diagn. 2023 Sep 4;2(6):1492-1500.
9. Nelson CC, Fraser MD, Wilfahrt JK, Foltz RL. Gas chromatography/tandem mass spectrometry measurement of delta 9-tetrahydrocannabinol, naltrexone, and their active metabolites in plasma. Ther Drug Monit. 1993 Dec;15(6):557-62.
10. Alffenaar JC, Jongedijk EM, van Winkel CAJ, Sariko M, Heysell SK, Mpagama S, Touw DJ. A mobile microvolume UV/visible light spectrophotometer for the measurement of levofloxacin in saliva. J Antimicrob Chemother. 2021 Jan 19;76(2):423-429.

11. Thomas SN, French D, Jannetto PJ, Rappold BA, Clarke WA. Liquid chromatography-tandem mass spectrometry for clinical diagnostics. Nat Rev Methods Primers. 2022;2(1):96.
12. Papamichael K, Stocco G, Ruiz Del Agua A. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases. Ther Drug Monit. 2023 Oct 1;45(5):579-590.
13. Kim HY, Byashalira KC, Heysell SK, Märtson AG, Mpagama SG, Rao P, Sturkenboom MGG, Alffenaar JC. Therapeutic Drug Monitoring of Anti-infective Drugs: Implementation Strategies for 3 Different Scenarios. Ther Drug Monit. 2022 Feb 1;44(1):3-10.
14. Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, Neely MN, Paiva JA, Pea F, Sjovall F, Timsit JF, Udy AA, Wicha SG, Zeitlinger M, De Waele JJ, Roberts JA; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med. 2020 Jun;46(6):1127-1153.
15. Poweleit EA, Vinks AA, Mizuno T. Artificial Intelligence and Machine Learning Approaches to Facilitate Therapeutic Drug Management and Model-Informed Precision Dosing. Ther Drug Monit. 2023 Apr 1;45(2):143-150.
16. Peng J, Jury EC, Dönnes P, et al. Machine learning techniques for personalised medicine approaches in immune-mediated chronic inflammatory diseases: applications and challenges. Front Pharmacol. 2021;12:720694
17. Poweleit EA, Vinks AA, Mizuno T. Artificial Intelligence and Machine Learning Approaches to Facilitate Therapeutic Drug Management and Model-Informed Precision Dosing. Ther Drug Monit. 2023 Apr 1;45(2):143-150.
18. Varela-Rey I, Bandín-Vilar E, Toja-Camba FJ, Cañizo-Outeiriño A, Cajade-Pascual F, Ortega-Hortas M, Mangas-Sanjuan V, González-Barcia M, Zarra-Ferro I, Mondelo-García C, et al. Artificial Intelligence and Machine Learning Applications to Pharmacokinetic Modeling and Dose Prediction of Antibiotics: A Scoping Review. *Antibiotics*. 2024; 13(12):1203.
19. Zidoum, Hamza & Alsawafi, Sumaya & Alansari, Aliya & Al Lawati, Batool. (2022). Unsupervised Learning Approach to Drive Therapeutic Precision in a Complex Disease. 1-7. 10.
20. Kalinin AA, Higgins GA, Reamaroon N, Soroushmehr S, Allyn-Feuer A, Dinov ID, Najarian K, Athey BD. Deep learning in pharmacogenomics: from gene regulation to patient stratification. Pharmacogenomics. 2018 May;19(7):629-650.
21. Hossain E, Rana R, Higgins N, Soar J, Barua PD, Pisani AR, Turner K. Natural Language Processing in Electronic Health Records in relation to healthcare decision-making: A systematic review. Comput Biol Med. 2023 Mar;155:106649.
22. van der Lee, Maaike & Swen, Jesse. (2022). Artificial intelligence in pharmacology research and practice. Clinical and Translational Science. 16. 10
23. Liu Y, Li J, Xiao S, Liu Y, Bai M, Gong L, Zhao J, Chen D. Revolutionizing Precision Medicine: Exploring Wearable Sensors for Therapeutic Drug Monitoring and Personalized Therapy. *Biosensors*. 2023; 13(7):726
24. Alowais SA, Alghamdi SS, Alsuhebany N, Alqahtani T, Alshaya AI, Almohareb SN, Aldairem A, Alrashed M, Bin Saleh K, Badreldin HA, Al Yami MS, Al Harbi S, Albekairy AM. Revolutionizing healthcare: the role of artificial intelligence in clinical

practice. BMC Med Educ. 2023 Sep 22;23(1):689.
25. Huang Z, Denti P, Mistry H, Kloprogge F. Machine Learning and Artificial Intelligence in PK-PD Modeling: Fad, Friend, or Foe? Clin Pharmacol Ther. 2024 Apr;115(4):652-654.
26. Lu, J. , Deng, K. , Zhang, X. , Liu, G. & Guan, Y. Neural-ODE for pharmacokinetics modeling and its advantage to alternative machine learning models in predicting new dosing regimens. iScience 24, 102804 (2021).
27. Yang J, Hu Z, Zhang L, Peng B. Predicting Drugs Suspected of Causing Adverse Drug Reactions Using Graph Features and Attention Mechanisms. Pharmaceuticals. 2024; 17(7):822.
28. Oluwaseyi, Joseph & Enoch, Olanite. (2024). AI in Predicting Adverse Drug Reactions: Enhancing Patient Safety.
29. Maleki Varnosfaderani S, Forouzanfar M. The Role of AI in Hospitals and Clinics: Transforming Healthcare in the 21st Century. Bioengineering (Basel). 2024 Mar 29;11(4):337.
30. Niazi SK. The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives. Drug Des Devel Ther. 2023 Sep 6;17:2691-2725.
31. Vo DK, Trinh KTL. Advances in Wearable Biosensors for Healthcare: Current Trends, Applications, and Future Perspectives. Biosensors (Basel). 2024 Nov 18;14(11):560.
32. Medanki S, Dommati N, Bodapati HH, Katru VNSK, Moses G, Komaraju A, Donepudi NS, Yalamanchili D, Sateesh J, Turimerla P. Artificial intelligence powered glucose monitoring and controlling system: Pumping module. World J Exp Med. 2024 Mar 20;14(1):87916.
33. Zhang Y, Deng Z, Xu X, Feng Y, Junliang S. Application of Artificial Intelligence in Drug-Drug Interactions Prediction: A Review. J Chem Inf Model. 2024 Apr 8;64(7):2158-2173.
34. Han R, Yoon H, Kim G, Lee H, Lee Y. Revolutionizing Medicinal Chemistry: The Application of Artificial Intelligence (AI) in Early Drug Discovery. Pharmaceuticals (Basel). 2023 Sep 6;16(9):1259.
35. Elhaddad M, Hamam S. AI-Driven Clinical Decision Support Systems: An Ongoing Pursuit of Potential. Cureus. 2024 Apr 6;16(4):e57728.
36. Elhaddad M, Hamam S. AI-Driven Clinical Decision Support Systems: An Ongoing Pursuit of Potential. Cureus. 2024 Apr 6;16(4):e57728
37. Rao M, Nassiri V, Srivastava S, Yang A, Brar S, McDuffie E, Sachs C. Artificial Intelligence and Machine Learning Models for Predicting Drug-Induced Kidney Injury in Small Molecules. Pharmaceuticals (Basel). 2024 Nov 19;17(11):1550.
38. Barrett JS. Artificial Intelligence Opportunities to Guide Precision Dosing Strategies. J Pediatr Pharmacol Ther. 2024 Aug;29(4):434-440.
39. Vidhya KS, Sultana A, M NK, Rangareddy H. Artificial Intelligence's Impact on Drug Discovery and Development From Bench to Bedside. Cureus. 2023 Oct 22;15(10):e47486.
40. Sopruchi, Ariowachukwu & Anguzu, Rashid & University II, Kampala International. (2024). The Integration of AI-Driven Decision Support Systems in Healthcare: Enhancements, Challenges, and Future Directions .Idosr Journal Of Computer And Applied Sciences. 9. 17-25.
41. Marques L, Costa B, Pereira M, Silva A, Santos J, Saldanha L, Silva I, Magalhães P, Schmidt S, Vale N. Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. Pharmaceutics. 2024; 16(3):332.
42. Arora A, Alderman JE, Palmer J, Ganapathi S, Laws E, McCradden MD, Oakden-Rayner L, Pfohl SR, Ghassemi M, McKay F, Treanor D, Rostamzadeh N, Mateen B, Gath J, Adebajo AO, Kuku S, Matin R, Heller K, Sapey E, Sebire NJ, Cole-Lewis H, Calvert M, Denniston A, Liu X. The value of standards for health datasets in artificial intelligence-based applications. Nat Med. 2023 Nov;29(11):2929-2938.
43. Chen RJ, Wang JJ, Williamson DFK, Chen TY, Lipkova J, Lu MY, Sahai S, Mahmood F. Algorithmic fairness in artificial intelligence

for medicine and healthcare. Nat Biomed Eng. 2023 Jun;7(6):719-742.
44. Lysaght T, Lim HY, Xafis V, Ngiam KY. AI-Assisted Decision-making in Healthcare: The Application of an Ethics Framework for Big Data in Health and Research. Asian Bioeth Rev. 2019 Sep 12;11(3):299-314.
45. Vasdev N, Gupta T, Pawar B, Bain A, Tekade RK. Navigating the future of health care with AI-driven digital therapeutics. Drug Discov Today. 2024 Sep;29(9):104110.

Access this Article in Online	
	Website: www.ijcrims.com
Quick Response Code	Subject: Pharmacogenomics
DOI: 10.22192/ijcrms.2025.11.02.008	

How to cite this article:
Ravva. Nikhil Gupta, Chilukoti. Mahesh Babu. (2025). Artificial intelligence and machine learning in therapeutic drug monitoring: Revolutionizing dosing and clinical decision support. Int. J. Curr. Res. Med. Sci. 11(2): 63-77.
DOI: http://dx.doi.org/10.22192/ijcrms.2025.11.02.008